IFN-β Therapy Regulates TLR7-Mediated Response in Plasmacytoid Dendritic Cells of Multiple Sclerosis Patients Influencing an Anti-Inflammatory Status.

Plasmacytoid dendritic cells (pDCs) display altered immune-phenotype in multiple sclerosis (MS) patients and are found actively recruited in postmortem MS brain lesions, implying that their immune regulation may represent an important aspect of MS pathogenesis. Because of the reported Toll-like receptor 7 (TLR7) implication in autoimmunity, in this study we characterized how IFN-β therapy impacts on pDC activation to TLR7 triggering in MS patients, aspect only poorly investigated so far. In vivo IFN-β administration regulates pDC functions in TLR7-treated peripheral blood mononuclear cell (PBMC) cultures differently from what is observed in isolated cells, suggesting that IFN-β may activate inhibitory mechanisms in MS peripheral blood involved in turning off pDC response to dampen the ongoing inflammation. Indeed, IL-10, a key regulatory cytokine found increased upon TLR7 stimulation in in vivo IFN-β-exposed PBMCs, directly reduced pDC-mediated IFN-α production. IFN-β therapy also shaped T-cell responses by decreasing TLR7-induced pDC maturation and inducing T-cell inhibitory molecules. Accordingly, raised pDC-induced IL-27 and decreased IL-23 expression, together with high IL-10 level, contribute to inhibit Th17 cell differentiation. Our study uncovered a role for IFN-β in the regulation of TLR7-mediated pDC responses in MS toward an anti-inflammatory phenotype opening new opportunities to better understand mechanisms of action of this drug in controlling MS immunopathogenesis.

[1]  E. Coccia,et al.  IFN-β and multiple sclerosis: cross-talking of immune cells and integration of immunoregulatory networks. , 2015, Cytokine & growth factor reviews.

[2]  K. Selmaj,et al.  Plasmocytoid dendritic cell deficit of early response to toll-like receptor 7 agonist stimulation in multiple sclerosis patients. , 2014, Clinical immunology.

[3]  Hongtu Zhu,et al.  The Role of Endogenous IFN-β in the Regulation of Th17 Responses in Patients with Relapsing-Remitting Multiple Sclerosis , 2014, The Journal of Immunology.

[4]  M. PennellLeesa,et al.  Immunoregulatory Effects of Interferon-β in Suppression of Th17 cells , 2014 .

[5]  E. Fish,et al.  Immunoregulatory effects of interferon-β in suppression of Th17 cells. , 2014, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[6]  F. Paul,et al.  Multiple Sclerosis: Modulation of Toll-Like Receptor (TLR) Expression by Interferon-β Includes Upregulation of TLR7 in Plasmacytoid Dendritic Cells , 2013, PloS one.

[7]  E. Coccia,et al.  IFN‐β therapy modulates B‐cell and monocyte crosstalk via TLR7 in multiple sclerosis patients , 2013, European journal of immunology.

[8]  A. Huțanu,et al.  Serum levels of IL-17A in patients with relapsing–remitting multiple sclerosis treated with interferon-β , 2013, Multiple sclerosis.

[9]  V. Soumelis,et al.  Human inflammatory dendritic cells induce Th17 cell differentiation. , 2013, Immunity.

[10]  M. Kvarnström,et al.  Longitudinal interferon-β effects in multiple sclerosis: Differential regulation of IL-10 and IL-17A, while no sustained effects on IFN-γ, IL-4 or IL-13 , 2013, Journal of the Neurological Sciences.

[11]  E. Coccia,et al.  EBV stimulates TLR‐ and autophagy‐dependent pathways and impairs maturation in plasmacytoid dendritic cells: Implications for viral immune escape , 2013, European journal of immunology.

[12]  C. Raman,et al.  Janus‐like effects of type I interferon in autoimmune diseases , 2012, Immunological reviews.

[13]  S. Kikuchi,et al.  Decreased interferon-α production in response to CpG DNA dysregulates cytokine responses in patients with multiple sclerosis. , 2012, Clinical immunology.

[14]  D. Dreyfus Autoimmune disease: A role for new anti-viral therapies? , 2011, Autoimmunity reviews.

[15]  A. Kawasaki,et al.  TLR7 single-nucleotide polymorphisms in the 3' untranslated region and intron 2 independently contribute to systemic lupus erythematosus in Japanese women: a case-control association study , 2011, Arthritis Research & Therapy.

[16]  A. Minagar An Imbalance of Two Functionally and Phenotypically Different Subsets of Plasmacytoid Dendritic Cells Characterizes the Dysfunctional Immune Regulation in Multiple Sclerosis , 2011 .

[17]  A. Damasceno,et al.  Plasmacytoid dendritic cells are increased in cerebrospinal fluid of untreated patients during multiple sclerosis relapse , 2011, Journal of Neuroinflammation.

[18]  H. Weiner,et al.  Interferon‐β inhibits toll‐like receptor 9 processing in multiple sclerosis , 2010, Annals of neurology.

[19]  E. Coccia,et al.  Epstein-Barr Virus Latent Infection and BAFF Expression in B Cells in the Multiple Sclerosis Brain: Implications for Viral Persistence and Intrathecal B-Cell Activation , 2010, Journal of neuropathology and experimental neurology.

[20]  P. Sørensen,et al.  Polymorphisms of innate pattern recognition receptors, response to interferon-beta and development of neutralizing antibodies in multiple sclerosis patients , 2010, Multiple sclerosis.

[21]  M. Colonna,et al.  Unraveling the functions of plasmacytoid dendritic cells during viral infections, autoimmunity, and tolerance , 2010, Immunological reviews.

[22]  E. Barillot,et al.  Multiparametric analysis of cytokine-driven human Th17 differentiation reveals a differential regulation of IL-17 and IL-22 production. , 2009, Blood.

[23]  Jianping Jin,et al.  IFN-β Inhibits Human Th17 Cell Differentiation1 , 2009, The Journal of Immunology.

[24]  H. Lassmann,et al.  Plasmacytoid DC promote priming of autoimmune Th17 cells and EAE , 2009, European journal of immunology.

[25]  R. Gold,et al.  Altered innate immune response of plasmacytoid dendritic cells in multiple sclerosis , 2009, Clinical and experimental immunology.

[26]  F. Sallusto,et al.  Human Th17 cells in infection and autoimmunity. , 2009, Microbes and infection.

[27]  Jianping Jin,et al.  IFN-β1a Inhibits the Secretion of Th17-Polarizing Cytokines in Human Dendritic Cells via TLR7 Up-Regulation1 , 2009, The Journal of Immunology.

[28]  Jianping Jin,et al.  Oligoclonal myelin-reactive T-cell infiltrates derived from multiple sclerosis lesions are enriched in Th17 cells. , 2009, Clinical immunology.

[29]  M. Gilliet,et al.  Plasmacytoid dendritic cells: sensing nucleic acids in viral infection and autoimmune diseases , 2008, Nature Reviews Immunology.

[30]  G. Rosati,et al.  Multiple sclerosis: reduced proportion of circulating plasmacytoid dendritic cells expressing BDCA-2 and BDCA-4 and reduced production of IL-6 and IL-10 in response to herpes simplex virus type 1 , 2008, Multiple sclerosis.

[31]  E. Coccia,et al.  Plasmacytoid Dendritic Cells in Multiple Sclerosis: Intracerebral Recruitment and Impaired Maturation in Response to Interferon-&bgr; , 2008, Journal of neuropathology and experimental neurology.

[32]  Y. Iwakura,et al.  Either a Th17 or a Th1 effector response can drive autoimmunity: conditions of disease induction affect dominant effector category , 2008, The Journal of experimental medicine.

[33]  A. Ascherio Epstein–Barr virus in the development of multiple sclerosis , 2008, Expert review of neurotherapeutics.

[34]  J. Goverman,et al.  Differential regulation of central nervous system autoimmunity by TH1 and TH17 cells , 2008, Nature Medicine.

[35]  J. O’Shea,et al.  Regulation of IL-17 production in human lymphocytes. , 2008, Cytokine.

[36]  J. Carl,et al.  IL27: its roles in the induction and inhibition of inflammation. , 2008, International journal of clinical and experimental pathology.

[37]  Jia Newcombe,et al.  Interleukin-17 production in central nervous system-infiltrating T cells and glial cells is associated with active disease in multiple sclerosis. , 2008, The American journal of pathology.

[38]  E. Coccia,et al.  IFN‐β modulates the response to TLR stimulation in human DC: Involvement of IFN regulatory factor‐1 (IRF‐1) in IL‐27 gene expression , 2007, European journal of immunology.

[39]  Graham R. Foster,et al.  Interferons at age 50: past, current and future impact on biomedicine , 2007, Nature Reviews Drug Discovery.

[40]  R. Reynolds,et al.  Dysregulated Epstein-Barr virus infection in the multiple sclerosis brain , 2007, The Journal of experimental medicine.

[41]  E. Bettelli,et al.  The dynamics of effector T cells and Foxp3+ regulatory T cells in the promotion and regulation of autoimmune encephalomyelitis , 2007, Journal of Neuroimmunology.

[42]  L. Lanier,et al.  BDCA2/FcɛRIγ Complex Signals through a Novel BCR-Like Pathway in Human Plasmacytoid Dendritic Cells , 2007, PLoS biology.

[43]  Masato Kubo,et al.  SOCS proteins, cytokine signalling and immune regulation , 2007, Nature Reviews Immunology.

[44]  E. Coccia,et al.  Sensitization to TLR7 Agonist in IFN-β-Preactivated Dendritic Cells1 , 2007, The Journal of Immunology.

[45]  X. Qin,et al.  Plasmacytoid dendritic cells prime IL-10–producing T regulatory cells by inducible costimulator ligand , 2007, The Journal of experimental medicine.

[46]  E. Coccia,et al.  Sensitization to TLR7 agonist in IFN-beta-preactivated dendritic cells. , 2007, Journal of immunology.

[47]  P. Murray Understanding and exploiting the endogenous interleukin-10/STAT3-mediated anti-inflammatory response. , 2006, Current opinion in pharmacology.

[48]  Wei Cao,et al.  Plasmacytoid dendritic cell–specific receptor ILT7–FcɛRIγ inhibits Toll-like receptor–induced interferon production , 2006, The Journal of experimental medicine.

[49]  X. Montalban,et al.  Altered maturation of circulating dendritic cells in primary progressive MS patients , 2006, Journal of Neuroimmunology.

[50]  R. Gold,et al.  Impaired maturation and altered regulatory function of plasmacytoid dendritic cells in multiple sclerosis. , 2006, Brain : a journal of neurology.

[51]  Wei Cao,et al.  Plasmacytoid dendritic cell-specific receptor ILT7-Fc epsilonRI gamma inhibits Toll-like receptor-induced interferon production , 2006 .

[52]  S. Reingold,et al.  Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria” , 2005, Annals of neurology.

[53]  P. Murray The primary mechanism of the IL-10-regulated antiinflammatory response is to selectively inhibit transcription. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[54]  Mary Collins,et al.  The B7 family of immune-regulatory ligands , 2005, Genome Biology.

[55]  V. Pascual,et al.  Cross-regulation of TNF and IFN-¿ in autoimmune diseases , 2005 .

[56]  V. Pascual,et al.  Cross-regulation of TNF and IFN-alpha in autoimmune diseases. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[57]  E. Coccia,et al.  Viral infection and Toll‐like receptor agonists induce a differential expression of type I and λ interferons in human plasmacytoid and monocyte‐derived dendritic cells , 2004, European journal of immunology.

[58]  R. Coffman,et al.  IMMUNOBIOLOGY: IL-10 Regulates Plasmacytoid Dendritic Cell Response to CpG Containing ImmunoStimulatory Sequences , 2003 .

[59]  R. Heller,et al.  Gene microarray analysis of multiple sclerosis lesions. , 2003, Trends in molecular medicine.

[60]  L. Rönnblom,et al.  FcγRIIa Is Expressed on Natural IFN-α-Producing Cells (Plasmacytoid Dendritic Cells) and Is Required for the IFN-α Production Induced by Apoptotic Cells Combined with Lupus IgG 1 , 2003, The Journal of Immunology.

[61]  L. Rönnblom,et al.  Fc gamma RIIa is expressed on natural IFN-alpha-producing cells (plasmacytoid dendritic cells) and is required for the IFN-alpha production induced by apoptotic cells combined with lupus IgG. , 2003, Journal of immunology.

[62]  Sankar Ghosh,et al.  Negative Regulation of Toll-like Receptor-mediated Signaling by Tollip* , 2002, The Journal of Biological Chemistry.

[63]  P. Kivisäkk,et al.  Interleukin-17 mRNA expression in blood and CSF mononuclear cells is augmented in multiple sclerosis , 1999, Multiple sclerosis.